Loading clinical trials...

COMPLETEDPhase 2NCT03100344

Dose-ranging Study of Nemolizumab in Atopic Dermatitis

Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately controlled with topic...

Lead sponsor: Galderma R&D•26 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGPhase 2

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

NCT07223697 · Atopic Dermatitis

RECRUITINGPhase 1

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

NCT07455578 · Autoimmune Diseases, Rheumatoid Arthritis (RA), and more

RECRUITING

Natural History and Genetics of Food Allergy and Related Conditions

NCT02504853 · Food Allergy, Loeys-Dietz Syndrome, and more

RECRUITINGPhase 2

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

NCT07355075 · Eczema Atopic Dermatitis, Eczema, and more

RECRUITING

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

NCT04455906 · Atopic Dermatitis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 22, 2019Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment226

Start dateJun 2017

Last updatedOct 22, 2019

Condition

Atopic Dermatitis

Locations shown

Galderma Investigational site

Birmingham, Alabama

Galderma Investigational site

Fort Smith, Arkansas

Galderma Investigational site

Beverly Hills, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 22, 2019Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dose-ranging Study of Nemolizumab in Atopic Dermatitis

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

Natural History and Genetics of Food Allergy and Related Conditions

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Trial snapshot

Condition

Locations shown

For caregivers